Merck Cash on Hand 2010-2023 | MRK
Merck cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Merck cash on hand for the quarter ending December 31, 2023 was $7.093B, a 46.23% decline year-over-year.
- Merck cash on hand for 2023 was $7.093B, a 46.23% decline from 2022.
- Merck cash on hand for 2022 was $13.192B, a 62.94% increase from 2021.
- Merck cash on hand for 2021 was $8.096B, a 0.57% increase from 2020.
Merck Annual Cash on Hand
(Millions of US $) |
| 2023 |
$7,093 |
| 2022 |
$13,192 |
| 2021 |
$8,096 |
| 2020 |
$8,050 |
| 2019 |
$10,450 |
| 2018 |
$8,864 |
| 2017 |
$8,498 |
| 2016 |
$14,341 |
| 2015 |
$13,427 |
| 2014 |
$15,719 |
| 2013 |
$17,486 |
| 2012 |
$16,141 |
| 2011 |
$14,972 |
| 2010 |
$12,201 |
| 2009 |
$9,604 |
Merck Quarterly Cash on Hand
(Millions of US $) |
| 2023-12-31 |
$7,093 |
| 2023-09-30 |
$8,773 |
| 2023-06-30 |
$6,378 |
| 2023-03-31 |
$10,387 |
| 2022-12-31 |
$13,192 |
| 2022-09-30 |
$11,248 |
| 2022-06-30 |
$10,128 |
| 2022-03-31 |
$8,928 |
| 2021-12-31 |
$8,096 |
| 2021-09-30 |
$10,016 |
| 2021-06-30 |
$8,575 |
| 2021-03-31 |
$6,981 |
| 2020-12-31 |
$8,050 |
| 2020-09-30 |
$7,356 |
| 2020-06-30 |
$11,103 |
| 2020-03-31 |
$7,432 |
| 2019-12-31 |
$10,450 |
| 2019-09-30 |
$8,018 |
| 2019-06-30 |
$7,105 |
| 2019-03-31 |
$8,798 |
| 2018-12-31 |
$8,864 |
| 2018-09-30 |
$10,285 |
| 2018-06-30 |
$7,594 |
| 2018-03-31 |
$7,346 |
| 2017-12-31 |
$8,498 |
| 2017-09-30 |
$11,195 |
| 2017-06-30 |
$11,967 |
| 2017-03-31 |
$15,249 |
| 2016-12-31 |
$14,341 |
| 2016-09-30 |
$13,067 |
| 2016-06-30 |
$11,834 |
| 2016-03-31 |
$12,943 |
| 2015-12-31 |
$13,427 |
| 2015-09-30 |
$12,089 |
| 2015-06-30 |
$11,370 |
| 2015-03-31 |
$15,601 |
| 2014-12-31 |
$15,719 |
| 2014-09-30 |
$14,347 |
| 2014-06-30 |
$13,395 |
| 2014-03-31 |
$20,513 |
| 2013-12-31 |
$17,486 |
| 2013-09-30 |
$18,169 |
| 2013-06-30 |
$18,098 |
| 2013-03-31 |
$16,022 |
| 2012-12-31 |
$16,141 |
| 2012-09-30 |
$18,117 |
| 2012-06-30 |
$17,450 |
| 2012-03-31 |
$15,566 |
| 2011-12-31 |
$14,972 |
| 2011-09-30 |
$15,576 |
| 2011-06-30 |
$13,981 |
| 2011-03-31 |
$13,029 |
| 2010-12-31 |
$12,201 |
| 2010-09-30 |
$10,625 |
| 2010-06-30 |
$9,943 |
| 2010-03-31 |
$9,777 |
| 2009-12-31 |
$9,604 |
| 2009-09-30 |
$22,256 |
| 2009-06-30 |
$16,932 |
| 2009-03-31 |
$12,582 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$321.543B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
